Ozempic Vision Loss Lawsuit — November 2026 Status: On November 9, 2026, the FDA required every GLP-1 drug label, including Ozempic, Wegovy, Mounjaro and Zepbound, to warn of a potential increased risk of NAION, a sudden optic-nerve injury that can permanently blind part or all of one eye. 278 lawsuits were pending in federal MDL 3163 in Philadelphia on November 2, 2026, up from 29 in January. The court is deciding general causation and warning adequacy first, and no trial is set. There is no settlement and no class action. State deadlines are as short as one year and usually start the day vision was lost. Free case review: 866-837-1010.
The Ozempic blindness lawsuit is a group of cases claiming that Ozempic, Wegovy and other GLP-1 drugs caused NAION (non-arteritic anterior ischemic optic neuropathy), and that Novo Nordisk and Eli Lilly did not warn American doctors or patients. NAION is sometimes called a stroke of the optic nerve. It is sudden, it is usually painless, and the vision it takes generally does not come back.
Fob & Foster Personal Injury Lawyers review Ozempic vision loss claims for people in Alabama, Georgia and Tennessee, and work with co-counsel for people in other states. This page covers who qualifies, what the FDA and the studies say, where the federal case stands, and how long you have. The call is free: 866-837-1010.
Filing Deadline Warning: Because NAION strikes suddenly, the clock usually starts the day you lost vision, not the day you read about a lawsuit. Tennessee generally allows one year. Alabama and Georgia generally allow two. The FDA’s November 2026 warning does not restart it. Call 866-837-1010 to have your date checked.
Who Qualifies for an Ozempic Vision Loss Lawsuit?
We look for three things, and each one comes from a record.
Do You Have an Ozempic Vision Loss Claim?
You may have a claim if all three are true:
- You took Ozempic, Wegovy, Mounjaro, Zepbound or another GLP-1 drug by prescription.
- An eye doctor diagnosed NAION, or you had sudden, painless loss of vision in one eye.
- The vision loss came after you started the drug.
All three? Call 866-837-1010 or send us a message. The review is free. We review vision loss claims only and are not taking stomach paralysis cases.
The diagnosis matters more than anything else. Sudden vision loss has several causes, and a claim depends on the eye doctor’s record saying NAION and explaining how the look-alikes were ruled out. If you used a compounded product from a med spa or an online clinic, call anyway. It was not made by Novo Nordisk or Eli Lilly, which raises a question about who made what you took, and we will look at what you received.
Ozempic Vision Loss Lawsuit Updates
Latest Update, November 9, 2026: FDA Requires a NAION Warning on Every GLP-1 Drug. On November 9, 2026, the FDA announced that it is requiring the makers of every GLP-1 drug, including Ozempic, Wegovy and Rybelsus (semaglutide) and Mounjaro and Zepbound (tirzepatide), to add a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of their labels. In its Drug Safety Communication, the agency found “a potential increased risk of rare NAION events” but did not conclude that the drugs cause NAION. Its review of 126 clinical trials counted 10 probable NAION events among patients on GLP-1 drugs and 5 among patients on placebo. Plaintiffs in MDL 3163 (278 cases pending as of November 2) allege the drugmakers should have warned of this risk sooner. The new label does not decide that question, the manufacturers deny the claims, and the warning does not restart or extend anyone’s filing deadline.
November 3, 2026: Master Complaint Reportedly Filed; 278 Cases Pending
The JPML’s November 2 report lists 278 actions in MDL 3163, up from 247 a month earlier. The NAION master complaint was reportedly filed under seal on October 28, as the court’s schedule required. In the separate gastroparesis MDL (4,082 cases), closing arguments on the drugmakers’ challenges to the plaintiffs’ general-causation experts were held October 13, and no ruling has been reported. The next status conferences are set for November 17 and December 15.
October 20, 2026: Master Complaint Due Next Week; Docket at 247 Cases
The JPML’s October 1 report listed 247 pending actions in MDL 3163, up 31 from September. The Master Complaint is due October 28, 2026, with status conferences scheduled for November 17 and December 15.
August 27, 2026: CMO 14 Sets the Discovery and Expert Schedule
Fact discovery closes December 18, 2026 (Lilly) and February 26, 2027 (Novo Nordisk); expert and Rule 702 deadlines follow in 2027.
July 2, 2026: CMO 12 Puts General Causation and Warning Adequacy First
Bellwether selection was deferred. Australia’s TGA added GLP-1 class warnings the same month.
June 2, 2026: Science Day in Philadelphia
Both sides presented the medicine of NAION and the GLP-1 drugs to Judge Marston.
December 15, 2025: JPML Creates MDL 3163
Federal NAION cases naming Ozempic, Wegovy, Saxenda and Trulicity were centralized in Philadelphia before Judge Karen S. Marston.
We keep this dated history in one place. Our state pages for Alabama, Georgia and Tennessee carry the latest update and link back here, and our Ozempic lawsuit update post summarizes each month.
Does Ozempic Cause Blindness?
That question is not settled, and it is the exact question the federal judge has put first. What exists today is a group of observational studies reporting more NAION among people taking semaglutide (the ingredient in Ozempic, Wegovy and Rybelsus) or other GLP-1 drugs than among comparison groups.
| Study | Who was studied | What it reported |
|---|---|---|
| Hathaway et al., JAMA Ophthalmology, July 2024 (Massachusetts Eye and Ear / Harvard) | Neuro-ophthalmology patients at one Boston hospital with type 2 diabetes or with overweight or obesity | NAION hazard ratio of 4.28 (diabetes group) and 7.64 (overweight or obesity group) for semaglutide versus other medications |
| Simonsen et al., Diabetes, Obesity and Metabolism, 2025 (Danish-Norwegian cohort) | Adults with type 2 diabetes in the national registries of Denmark and Norway | Pooled NAION hazard ratio of 2.81 for semaglutide versus SGLT2 inhibitors, another class of diabetes drug |
| Choi, Al-Aly and Xie, JAMA Network Open, April 2026 (U.S. veterans) | 588,168 U.S. veterans with type 2 diabetes starting a GLP-1 drug or an SGLT2 inhibitor | 39.07 NAION cases per 10,000 over three years among GLP-1 starters versus 29.33 among SGLT2 inhibitor starters |
Read those numbers carefully. A hazard ratio of 4.28 means roughly four times the rate. It does not mean four in ten people lose vision. Europe’s drug regulator classifies NAION as a very rare side effect of semaglutide, affecting up to 1 in 10,000 people, and the veterans study found a difference of about ten cases per 10,000 people over three years.
The companies will argue confounding: people on these drugs often have diabetes, high blood pressure or sleep apnea, and each is tied to NAION on its own. Plaintiffs’ experts will point to consistent findings across countries, comparisons against other diabetes drugs, and regulators acting on the evidence. Plaintiffs’ expert reports are due March 26, 2027, and challenges to those experts are due July 2, 2027. That is when the science gets tested in court.
What NAION Is and What It Does to Your Sight
The optic nerve carries what the eye sees to the brain. Where it enters the back of the eye, it is fed by very small blood vessels. NAION happens when blood flow to that segment drops and the nerve tissue is starved of oxygen. The nerve fibers that are lost do not grow back.
Many people notice it on waking. Part of the vision in one eye is dim, blurry or gone, often the upper or lower half. There is usually no pain. The loss is frequently permanent, though some eyes improve a little over the following months. Someone who has had NAION in one eye also faces a risk to the other eye later.
Your Sight Comes First: Sudden vision loss in one eye is an emergency. See an eye doctor or go to an emergency room the same day so that other causes, including stroke and giant cell arteritis, can be ruled out. Do not stop a prescribed GLP-1 drug without talking to the doctor who prescribed it.
Get seen right away for any of these:
- Sudden blurring, dimming or a dark shadow over part of the vision in one eye
- Loss of the top or bottom half of what you see out of one eye
- Colors that look washed out in one eye compared with the other
- New vision loss along with headache, scalp tenderness or jaw pain when chewing
No treatment has been proven to restore vision lost to NAION, but a same-day exam still matters. It rules out giant cell arteritis, a blood-vessel inflammation that can take the second eye, and it creates the record a claim stands on.
The FDA’s November 2026 Warning and What Other Regulators Did
| Regulator | What it did | When |
|---|---|---|
| U.S. Food and Drug Administration | Listed NAION for GLP-1 drugs on its quarterly potential-signal list; then required every GLP-1 drug label to warn of a potential increased risk of NAION | Q4 2024 list; November 9, 2026 |
| European Medicines Agency safety committee | Concluded NAION is a very rare side effect of semaglutide (up to 1 in 10,000) | June 2025 |
| U.K. MHRA | Drug Safety Update: semaglutide may very rarely be linked to NAION; stop semaglutide if NAION is confirmed | February 2026 |
| Australia’s TGA | Added NAION information for all GLP-1 drugs, noting the class-wide update does not imply a causal link | July 2026 |
That gap is the center of the failure-to-warn claim. European regulators reached their conclusion in June 2025. A doctor in the United States writing an Ozempic prescription that year had no NAION warning on the U.S. label to pass along, and the FDA did not require one until November 9, 2026.
The companies will say the FDA saw the same signal and did not require a warning sooner. Under Wyeth v. Levine (U.S. Supreme Court, 2009), though, a brand-name manufacturer is responsible for its own label and can strengthen a warning through the FDA’s “changes being effected” process. Whether these companies should have is part of the warning-adequacy phase of the federal case.
Which Drugs and Companies Are in the Lawsuit?
| Brand | Active ingredient | Maker | In MDL 3163 |
|---|---|---|---|
| Ozempic | Semaglutide (weekly injection) | Novo Nordisk | Named at creation |
| Wegovy | Semaglutide | Novo Nordisk | Named at creation |
| Rybelsus | Semaglutide (daily tablet) | Novo Nordisk | Not named in the transfer order |
| Saxenda | Liraglutide | Novo Nordisk | Named at creation |
| Trulicity | Dulaglutide | Eli Lilly | Named at creation |
| Mounjaro | Tirzepatide | Eli Lilly | Later complaints |
| Zepbound | Tirzepatide | Eli Lilly | Not named in the transfer order |
The brand decides who you sue and how deep the evidence runs. Most of the published NAION research, including the Harvard study and the European conclusion, concerns semaglutide. Claims involving Trulicity, Mounjaro and Zepbound lean harder on arguments about the whole drug class, and we will say so up front. If you switched brands when your insurance changed, both companies may be involved, and your pharmacy history has to show which drug you were on before your vision changed.
Is There an Ozempic Blindness Class Action Lawsuit?
No. The NAION cases are individual lawsuits grouped in a multidistrict litigation, MDL 3163, for pretrial work. Each person proves his or her own injury and recovers his or her own damages. Nobody is included automatically, there is no claim form, and a person who does not file within the state deadline is not part of anything.
Where the Federal Case Stands
On December 15, 2025, the Judicial Panel on Multidistrict Litigation created MDL 3163 in the Eastern District of Pennsylvania in Philadelphia, before Judge Karen S. Marston, with Novo Nordisk and Eli Lilly as defendants. The docket has grown every month since.
| JPML report | Pending actions |
|---|---|
| January 2026 | 29 |
| June 2026 | 110 |
| August 2026 | 200 |
| September 2026 | 216 |
| October 1, 2026 | 247 |
| November 2, 2026 | 278 |
The November figure is from the JPML’s pending-dockets report. The court’s Case Management Order 12 (July 2, 2026) put general causation and warning adequacy first, and Case Management Order 14 (August 27, 2026) set these dates:
| Event | Date |
|---|---|
| Master Complaint due | October 28, 2026 |
| Status conferences | November 17 and December 15, 2026 |
| Eli Lilly fact discovery closes | December 18, 2026 |
| Novo Nordisk fact discovery closes | February 26, 2027 |
| Plaintiffs’ expert reports due | March 26, 2027 |
| Rule 702 and summary judgment motions due | July 2, 2027 |
| Opposition and reply briefs due | August 13 and August 31, 2027 |
So there will be no NAION trial in this MDL in 2026, and the causation fight will be fully briefed by August 31, 2027. If the plaintiffs clear that stage, the court has said bellwether selection can follow quickly. If they do not, many federal cases could face dismissal. A separate group of NAION cases is pending in New Jersey state court before Judge Gregg A. Padovano in Bergen County, and which court fits a claim is decided with co-counsel one case at a time.
You will usually not travel to Philadelphia. Your part is records, a fact sheet and calls with us. If your case is picked for closer work, a deposition is generally arranged near home.
Has There Been an Ozempic Vision Loss Settlement?
No. There is no settlement, no fund and no verdict, and any dollar range you see online is a projection. Our posts on Ozempic lawsuit settlement amounts and when the Ozempic lawsuit will be settled explain why no real number exists and what has to happen first.
What drives the value of a vision loss claim can be stated honestly: how much sight was lost and whether it is permanent, medical costs already incurred and expected, lost income and reduced earning capacity when vision loss ends or changes a career, the effect on driving and daily life, the strength of the timeline connecting the prescription to the vision loss, and whether the evidence supports punitive damages based on what the manufacturers knew and when.
Diabetes, Sleep Apnea and the Other Explanations the Defense Will Offer
The established risk factors for NAION are diabetes, high blood pressure, obesity and sleep apnea. Those are largely the conditions these drugs are prescribed to treat, so nearly every plaintiff has at least one. The defense will say the disease caused the vision loss, not the drug.
That does not end a claim. It makes the medical work more detailed. The studies that matter compared GLP-1 users with similar patients on other drugs, which is the way to separate a drug effect from the underlying disease. In an individual case, the record of how well your conditions were controlled, when you started the drug and when your vision changed carries the weight. Have the records reviewed before you rule yourself out.
Records That Prove a NAION Claim
- The eye record. An ophthalmology or neuro-ophthalmology note that says NAION and explains how other causes were excluded, including blood tests for giant cell arteritis.
- Pharmacy history showing which GLP-1 drug you were on, the dose and the dates, before your vision changed.
- Prescriber records, which show why the drug was prescribed and what you were told.
- Visual field tests and imaging, which measure what was lost.
- Work and driving records, if the vision loss changed your job or your license.
We request records for you once you hire us, at no upfront cost.
How Long Do You Have to File?
Your state’s law sets the deadline:
- Alabama: generally two years (Ala. Code § 6-2-38). For a vision loss claim the clock usually starts at the injury. See our Alabama page.
- Georgia: generally two years (O.C.G.A. § 9-3-33). Because NAION strikes suddenly, the clock generally runs from the day you lost vision. See our Georgia page.
- Tennessee: generally one year (Tenn. Code Ann. § 28-3-104). See our Tennessee page.
Do not count from the FDA’s November 2026 warning, and do not count from the day you first heard about a lawsuit. If your vision loss happened in 2024 or 2025, call now. If you live in another state, we will check that state’s deadline with co-counsel.
Ozempic Stomach Paralysis Cases Are Separate
Most headlines about Ozempic lawsuits concern gastroparesis and other stomach and bowel injuries. Those cases are in a different federal proceeding, MDL 3094, before the same judge, with 4,082 pending as of November 2, 2026. Fob & Foster Personal Injury Lawyers are not taking stomach paralysis cases. We review vision loss claims only.
What to Do This Week If You Lost Vision on a GLP-1 Drug
- See an eye doctor if you have not, and ask whether the diagnosis is NAION.
- Do not stop or change your prescription on your own. Tell the prescriber about the eye diagnosis and decide together.
- Ask your pharmacy for a printed fill history with drug names and dates.
- Write down the date your vision changed and what you noticed.
- Call us so we can check your state’s deadline.
How We Work
- You talk to a lawyer about your dates and records, by phone or video.
- No fee unless we recover money for you. The consultation is free.
- Licensed where you live. Fob James IV is licensed in Alabama, Georgia and Tennessee, and we work with co-counsel in the federal MDL and for people in other states.
- A straight answer. If the records do not support a claim, we say so in the review.
Ozempic Vision Loss Lawsuit FAQs
Is there an Ozempic blindness lawsuit?
Yes. People who developed NAION, a sudden and usually permanent loss of vision, while taking Ozempic or another GLP-1 drug have sued Novo Nordisk and Eli Lilly. The federal cases are in MDL 3163 in Philadelphia, where 278 were pending as of November 2, 2026.
Does Ozempic cause blindness?
That has not been decided. Several studies report more NAION among people taking semaglutide or other GLP-1 drugs than among comparison groups, and European regulators call NAION a very rare side effect of semaglutide. On November 9, 2026, the FDA required a warning of a potential increased risk but did not conclude that the drugs cause NAION. The drugmakers deny the claims.
Who qualifies for an Ozempic vision loss lawsuit?
The typical claim involves someone who took a GLP-1 drug by prescription, was diagnosed with NAION by an eye doctor, and lost vision after starting the drug. Pharmacy records and an ophthalmology or neuro-ophthalmology record are the core proof.
Is there an Ozempic vision loss class action?
No. Each person files an individual lawsuit, and the federal cases are grouped in MDL 3163 for pretrial work. Nothing is filed for you automatically, and you must file within your own state’s deadline.
Has the Ozempic vision loss lawsuit been settled?
No. There is no settlement, no trial date and no payout. The court has put the question of general causation first, and that briefing runs through August 31, 2027.
Does the FDA’s November 2026 warning help my case?
It supports the argument that a warning was needed, which is the heart of a failure-to-warn claim. It does not prove the drug caused your vision loss, and it does not restart or extend your filing deadline.
What if I took Wegovy, Mounjaro or Zepbound and not Ozempic?
You may still have a claim. Ozempic, Wegovy, Saxenda and Trulicity were named when the MDL was created, and later complaints name Mounjaro. Most of the published research concerns semaglutide, so claims involving the Eli Lilly drugs lean more on evidence about the drug class.
Does having diabetes or sleep apnea rule out a claim?
No. Most people prescribed these drugs have diabetes or obesity, and both are NAION risk factors on their own. The defense will raise them, which makes the medical work more detailed. They do not automatically defeat a claim.
How long do I have to file an Ozempic vision loss lawsuit?
It depends on your state. Tennessee generally allows one year, and Alabama and Georgia generally allow two. Because NAION strikes suddenly, the clock usually starts the day you lost vision.
Do you take Ozempic stomach paralysis cases?
No. Fob & Foster Personal Injury Lawyers review vision loss claims only. The stomach paralysis cases are a separate federal proceeding, MDL 3094.
Talk to an Ozempic Vision Loss Lawyer
If you lost vision while taking Ozempic, Wegovy, Mounjaro, Zepbound or another GLP-1 drug, call Fob & Foster Personal Injury Lawyers at 866-837-1010 or request a free case review online. We will ask when you started the drug, when your vision changed and what the eye doctor found. Then we will tell you whether the claim fits the current cases and how much time your state likely leaves you.